Bull
$14.87
Precio del escenario
$9.440
-0.128 (-1.36%)Al cierre
Alphatec Holdings, Inc., through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S. and SafeOp Surgical, Inc., is a medical device company. It is focused on the design, development, and advancement of technology for better surgical treatment of spine disorders. Its Organic Innovation Machine is focused on developing new approaches that integrate with its expanding InformatiX Platform to better inform surgery and safely and reproducibly achieve the goals of spine surgery. Its technologies include InformatiX, positioners, access systems, implants and fixation systems, and biologics. Its InformatiX product platform comprises EOS imaging system, EOS Insight alignment assessment and surgical planning web/mobile platform, SafeOp Neural InformatiX System and navigation-enabled robotics platform. It has developed approach-specific patient positioning systems that integrate with its other access systems, providing for a more rigid construct and enhanced reproducibility.
Alphatec Holdings Inc is a good buy right now due to its recent revenue growth of 17% year-over-year in Q2 2026, reaching $214 million, and a gross margin improvement to 70.34%. The stock is currently priced at $9.44, significantly below the analyst price target of $15, indicating a potential upside of approximately 58%. However, investors should be cautious of the high forward P/E ratio of 384.62, which suggests that the stock may be overvalued if growth does not continue as expected.
BMO Capital
$12
2026-08-05
BMO Capital
2026-08-05
Precio objetivo
$12
UBS
$15
2026-07-28
UBS
2026-07-28
Precio objetivo
$15
Stephens
$15
2026-07-23
Stephens
2026-07-23
Precio objetivo
$15
Stifel
$13
2026-07-08
Stifel
2026-07-08
Precio objetivo
$13
Barclays
$24
2026-05-07
Barclays
2026-05-07
Precio objetivo
$24
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Alphatec (ATEC) Q2 2026 Earnings Call Transcript

Alphatec Holdings Q2 2026 Earnings Highlights

Latest Wall Street Rating Changes

Alphatec Announces Upcoming Investor Conference Participation

Alphatec to Report Q2 2026 Financial Results on August 4
Alphatec Holdings, Inc., through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S. and SafeOp Surgical, Inc., is a medical device company. It is focused on the design, development, and advancement of technology for better surgical treatment of spine disorders. Its Organic Innovation Machine is focused on developing new approaches that integrate with its expanding InformatiX Platform to better inform surgery and safely and reproducibly achieve the goals of spine surgery. Its technologies include InformatiX, positioners, access systems, implants and fixation systems, and biologics. Its InformatiX product platform comprises EOS imaging system, EOS Insight alignment assessment and surgical planning web/mobile platform, SafeOp Neural InformatiX System and navigation-enabled robotics platform. It has developed approach-specific patient positioning systems that integrate with its other access systems, providing for a more rigid construct and enhanced reproducibility. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
Alphatec Holdings Inc is a good buy right now due to its recent revenue growth of 17% year-over-year in Q2 2026, reaching $214 million, and a gross margin improvement to 70.34%. The stock is currently priced at $9.44, significantly below the analyst price target of $15, indicating a potential upside of approximately 58%. However, investors should be cautious of the high forward P/E ratio of 384.62, which suggests that the stock may be overvalued if growth does not continue as expected.
3 analysts cover ATEC: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 24.33.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.